Charles Antzelevitch, Facc

List of Publications by Year in Descending Order

442 papers	40,376 citations	102 h-index	191 g-index
498 ext. papers	45,066 ext. citations	6.1 avg, IF	7.51 L-index

#	Paper	IF	Citations
442	Increased susceptibility to ventricular arrhythmia at low-normal and moderately-low levels of extracellular potassium in Catecholaminergic Polymorphic Ventricular Tachycardia.. *Heart Rhythm*, **2022**,	6.7	
441	Distinct Features of Probands With Early Repolarization and Brugada Syndromes Carrying SCN5A Pathogenic Variants. *Journal of the American College of Cardiology*, **2021**, 78, 1603-1617	15.1	2
440	Clinical and Functional Genetic Characterization of the Role of Cardiac Calcium Channel Variants in the Early Repolarization Syndrome. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 680819	5.4	2
439	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. *Genetics in Medicine*, **2021**, 23, 47-58	8.1	13
438	Fractionated Epicardial Electrograms: Implication for Mechanism of the Brugada Pattern. *JACC: Clinical Electrophysiology*, **2021**, 7, 258-270	4.6	0
437	J wave syndromes: What's new?. *Trends in Cardiovascular Medicine*, **2021**,	6.9	1
436	Frequency of Irritable Bowel Syndrome in Patients with Brugada Syndrome and Drug-Induced Type 1 Brugada Pattern. *American Journal of Cardiology*, **2021**, 151, 51-56	3	
435	Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk. *Heart Rhythm*, **2021**, 18, 2177-2186	6.7	0
434	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. *Circulation*, **2020**, 142, 324-338	16.7	27
433	Abnormal myocardial expression of SAP97 is associated with arrhythmogenic risk. *American Journal of Physiology - Heart and Circulatory Physiology*, **2020**, 318, H1357-H1370	5.2	5
432	Identification, clinical manifestation and structural mechanisms of mutations in AMPK associated cardiac glycogen storage disease. *EBioMedicine*, **2020**, 54, 102723	8.8	5
431	Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes. *PLoS ONE*, **2020**, 15, e0242747	3.7	7
430	J Wave Syndromes: Brugada and Early Repolarization Syndromes. *Contemporary Cardiology*, **2020**, 745-774	0.1	
429	Mechanisms Underlying the Development of Cardiac Arrhythmias. *Contemporary Cardiology*, **2020**, 33-74	0.1	
428	Genetics, Molecular Biology, and Emerging Concepts of Early Repolarization Syndrome **2020**, 255-268		
427	Short QT Syndrome. *Contemporary Cardiology*, **2020**, 845-866	0.1	
426	Recognition and clinical implications of high prevalence of migraine in patients with Brugada syndrome and drug-induced type 1 Brugada pattern. *Journal of Cardiovascular Electrophysiology*, **2020**, 31, 3311-3317	2.7	3

425	Inherited cardiac arrhythmias. *Nature Reviews Disease Primers*, **2020**, 6, 58	51.1	53
424	Inter-Regulation of K4.3 and Voltage-Gated Sodium Channels Underlies Predisposition to Cardiac and Neuronal Channelopathies. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	3
423	GSTM3 variant is a novel genetic modifier in Brugada syndrome, a disease with risk of sudden cardiac death. *EBioMedicine*, **2020**, 57, 102843	8.8	9
422	Susceptibility to Ventricular Arrhythmias Resulting from Mutations in , , and Evaluated in hiPSC Cardiomyocytes. *Stem Cells International*, **2020**, 2020, 8842398	5	4
421	The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity. *Journal of Cardiovascular Pharmacology*, **2020**, 76, 164-172	3.1	5
420	Reply to the Editor- Tpeak-Tend is alive and well. *Heart Rhythm*, **2019**, 16, e49-e50	6.7	3
419	Mutations in Na1.5 Reveal Calcium-Calmodulin Regulation of Sodium Channel. *Frontiers in Physiology*, **2019**, 10, 700	4.6	7
418	Transcriptional changes associated with advancing stages of heart failure underlie atrial and ventricular arrhythmogenesis. *PLoS ONE*, **2019**, 14, e0216928	3.7	2
417	Mechanisms Underlying Arrhythmogenesis in the J-wave Syndromes **2019**, 351-363		
416	Evaluating the Impact of Sex and Gender in Brugada Syndrome. *Journal of Innovations in Cardiac Rhythm Management*, **2019**, 10, 3530-3535	1.1	1
415	Multiple serial ECGs aid with the diagnosis and prognosis of Brugada syndrome. *International Journal of Cardiology*, **2019**, 277, 130-135	3.2	6
414	Tpeak-Tend interval as a marker of arrhythmic risk. *Heart Rhythm*, **2019**, 16, 954-955	6.7	14
413	Effect of autonomic influences to induce triggered activity in muscular sleeves extending into the coronary sinus of the canine heart and its suppression by ranolazine. *Journal of Cardiovascular Electrophysiology*, **2019**, 30, 230-238	2.7	2
412	Cardiac Arrhythmias Related to Sodium Channel Dysfunction. *Handbook of Experimental Pharmacology*, **2018**, 246, 331-354	3.2	24
411	Impact of Ancestral Differences and Reassessment of the Classification of Previously Reported Pathogenic Variants in Patients With Brugada Syndrome in the Genomic Era: A SADS-TW BrS Registry. *Frontiers in Genetics*, **2018**, 9, 680	4.5	6
410	Pooled Analysis of Risk Stratification of Spontaneous Type 1 Brugada ECG: Focus on the Influence of Gender and EPS. *Frontiers in Physiology*, **2018**, 9, 1951	4.6	8
409	Shanghai Score System for Diagnosis of Brugada Syndrome: Validation of the Score System and System and Reclassification of the Patients. *JACC: Clinical Electrophysiology*, **2018**, 4, 724-730	4.6	21
408	Genetic, Ionic, and Cellular Mechanisms Underlying the J Wave Syndromes **2018**, 483-493		1

407	Coexistence of atrioventricular accessory pathways and drug-induced type 1 Brugada pattern. *PACE - Pacing and Clinical Electrophysiology*, **2018**, 41, 1078-1092	1.6	9
406	J wave syndromes as a cause of malignant cardiac arrhythmias. *PACE - Pacing and Clinical Electrophysiology*, **2018**, 41, 684-699	1.6	9
405	Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. *Arrhythmia and Electrophysiology Review*, **2018**, 7, 199-209	3.2	18
404	Epicardial Substrate as a Target for Radiofrequency Ablation in an Experimental Model of Early Repolarization Syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2018**, 11, e006511	6.4	6
403	Is extensive atrial fibrosis in the setting of heart failure associated with a reduced atrial fibrillation burden?. *PACE - Pacing and Clinical Electrophysiology*, **2018**, 41, 1289-1297	1.6	3
402	Recent advances in the treatment of Brugada syndrome. *Expert Review of Cardiovascular Therapy*, **2018**, 16, 387-404	2.5	11
401	Mechanisms Underlying Epicardial Radiofrequency Ablation to Suppress Arrhythmogenesis in Experimental Models of Brugada Syndrome. *JACC: Clinical Electrophysiology*, **2017**, 3, 353-363	4.6	24
400	The Phenotypic Spectrum of a Mutation Hotspot Responsible for the Short QT Syndrome. *JACC: Clinical Electrophysiology*, **2017**, 3, 727-743	4.6	24
399	Andersen-Tawil syndrome: Clinical presentation and predictors of symptomatic arrhythmias - Possible role of polymorphisms K897T in KCNH2 and H558R in SCN5A gene. *Journal of Cardiology*, **2017**, 70, 504-510	3	10
398	Pathophysiology of Atrial Fibrillation. *Cardiovascular Medicine*, **2017**, 15-25	0.1	1
397	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. *Europace*, **2017**, 19, 665-694	3.9	127
396	Risk stratification in Brugada syndrome: Clinical characteristics, electrocardiographic parameters, and auxiliary testing. *Heart Rhythm*, **2016**, 13, 299-310	6.7	65
395	Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects. *Current Problems in Cardiology*, **2016**, 41, 7-57	17.1	69
394	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. *Heart Rhythm*, **2016**, 13, e295-324	6.7	166
393	Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data. *Circulation: Arrhythmia and Electrophysiology*, **2016**, 9,	6.4	43
392	J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. *Journal of Arrhythmia*, **2016**, 32, 315-339	1.5	90
391	Further Insights in the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction Defect. *Journal of the American Heart Association*, **2016**, 5,	6	30
390	Molecular and Functional Characterization of Rare CACNA1C Variants in Sudden Unexplained Death in the Young. *Congenital Heart Disease*, **2016**, 11, 683-692	3.1	16

389	Atrial fibrillation in inherited cardiac channelopathies: From mechanisms to management. *Heart Rhythm*, **2016**, 13, 1878-84	6.7	21
388	Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis. *International Journal of Cardiology*, **2016**, 207, 326-34	3.2	15
387	Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis. *Circulation*, **2016**, 133, 622-30	16.7	138
386	Prognostic significance of fever-induced Brugada syndrome. *Heart Rhythm*, **2016**, 13, 1515-20	6.7	46
385	Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome. *Heart Rhythm*, **2016**, 13, 1326-34	6.7	15
384	Ionic and Cellular Mechanisms Underlying J Wave Syndromes **2016**, 33-76		
383	Atria are More Sensitive Than Ventricles to GS-458967-Induced Inhibition of Late Sodium Current. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2015**, 20, 501-8	2.6	15
382	The Early Repolarization Pattern: A Consensus Paper. *Journal of the American College of Cardiology*, **2015**, 66, 470-7	15.1	229
381	Novel Therapeutic Strategies for the Management of Ventricular Arrhythmias Associated with the Brugada Syndrome. *Expert Opinion on Orphan Drugs*, **2015**, 3, 633-651	1.1	14
380	Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation. *Heart Rhythm*, **2015**, 12, 836-44	6.7	11
379	J-wave syndromes: Brugada and early repolarization syndromes. *Heart Rhythm*, **2015**, 12, 1852-66	6.7	90
378	Traditional Chinese Medicine and Vascular Disease. *Evidence-based Complementary and Alternative Medicine*, **2015**, 2015, 430818	2.3	5
377	High prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant tachycardia. *Heart Rhythm*, **2015**, 12, 1584-94	6.7	63
376	Usefulness of exercise test in the diagnosis of short QT syndrome. *Europace*, **2015**, 17, 628-34	3.9	27
375	Novel Timothy syndrome mutation leading to increase in CACNA1C window current. *Heart Rhythm*, **2015**, 12, 211-9	6.7	59
374	Management of ventricular arrhythmias in suspected channelopathies. *Circulation: Arrhythmia and Electrophysiology*, **2015**, 8, 221-31	6.4	20
373	Calcium Channel Mutations in Cardiac Arrhythmia Syndromes. *Current Molecular Pharmacology*, **2015**, 8, 133-42	3.7	41
372	Abnormal repolarization as the basis for late potentials and fractionated electrograms recorded from epicardium in experimental models of Brugada syndrome. *Journal of the American College of Cardiology*, **2014**, 63, 2037-45	15.1	84

371	Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. *Journal of the American College of Cardiology*, **2014**, 64, 66-79	15.1	164
370	Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure. *Circulation: Heart Failure*, **2014**, 7, 627-33	7.6	30
369	PQ segment depression in patients with short QT syndrome: a novel marker for diagnosing short QT syndrome?. *Heart Rhythm*, **2014**, 11, 1024-30	6.7	24
368	Reply to the Editor--PQ-segment depression in short QT syndrome patients: a novel marker for diagnosing short QT syndrome?. *Heart Rhythm*, **2014**, 11, e8	6.7	1
367	Acute myocardial ischemia: cellular mechanisms underlying ST segment elevation. *Journal of Electrocardiology*, **2014**, 47, 486-90	1.4	37
366	Mechanisms underlying the development of the electrocardiographic and arrhythmic manifestations of early repolarization syndrome. *Journal of Molecular and Cellular Cardiology*, **2014**, 68, 20-8	5.8	88
365	A CACNA1C variant associated with reduced voltage-dependent inactivation, increased CaV1.2 channel window current, and arrhythmogenesis. *PLoS ONE*, **2014**, 9, e106982	3.7	31
364	Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. *Circulation: Arrhythmia and Electrophysiology*, **2014**, 7, 134-42	6.4	55
363	A temporal window of vulnerability for development of atrial fibrillation with advancing heart failure. *European Journal of Heart Failure*, **2014**, 16, 271-80	12.3	13
362	ABCC9 is a novel Brugada and early repolarization syndrome susceptibility gene. *International Journal of Cardiology*, **2014**, 171, 431-42	3.2	95
361	The role of late I Na in development of cardiac arrhythmias. *Handbook of Experimental Pharmacology*, **2014**, 221, 137-68	3.2	101
360	Genetics and Cellular Mechanisms of the J Wave Syndromes **2014**, 511-519		1
359	Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. *Nature Genetics*, **2013**, 45, 1044-9	36.3	345
358	Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. *Heart Rhythm*, **2013**, 10, 1720-7	6.7	44
357	Developmental changes in expression and biophysics of ion channels in the canine ventricle. *Journal of Molecular and Cellular Cardiology*, **2013**, 64, 79-89	5.8	13
356	Electrophysiologic characteristics and pharmacologic response of human cardiomyocytes isolated from a patient with hypertrophic cardiomyopathy. *PACE - Pacing and Clinical Electrophysiology*, **2013**, 36, 1512-5	1.6	12
355	J wave syndromes: molecular and cellular mechanisms. *Journal of Electrocardiology*, **2013**, 46, 510-8	1.4	62
354	Fever-induced Brugada pattern: how common is it and what does it mean?. *Heart Rhythm*, **2013**, 10, 1375-82	6.7	101

353	The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. *Cardiovascular Research*, **2013**, 99, 600-11	9.9	87
352	Optical and electrical recordings from isolated coronary-perfused ventricular wedge preparations. *Journal of Molecular and Cellular Cardiology*, **2013**, 54, 53-64	5.8	40
351	Role of late sodium channel current block in the management of atrial fibrillation. *Cardiovascular Drugs and Therapy*, **2013**, 27, 79-89	3.9	36
350	Drug-induced Brugada syndrome. *Journal of Arrhythmia*, **2013**, 29, 88-95	1.5	6
349	Effect of Wenxin Keli and quinidine to suppress arrhythmogenesis in an experimental model of Brugada syndrome. *Heart Rhythm*, **2013**, 10, 1054-62	6.7	42
348	Ventricular fibrillation associated with complete right bundle branch block. *Heart Rhythm*, **2013**, 10, 1028-35	6.7	16
347	Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967. *Heart Rhythm*, **2013**, 10, 1036-43	6.7	69
346	Authors' response to letter to the editor from Perez and Froelicher. *Journal of Electrocardiology*, **2013**, 46, 116; discussion 117	1.4	
345	Cardiomyocyte calcium cycling in a naturally occurring German shepherd dog model of inherited ventricular arrhythmia and sudden cardiac death. *Journal of Veterinary Cardiology*, **2013**, 15, 5-14	1.9	6
344	Mechanisms of Cardiac Arrhythmia **2013**, 93-128		
343	Extending the conditions of application of an inversion of the Hodgkin-Huxley gating model. *Bulletin of Mathematical Biology*, **2013**, 75, 752-73	2.1	7
342	Identification and characterization of a transient outward K+ current in human induced pluripotent stem cell-derived cardiomyocytes. *Journal of Molecular and Cellular Cardiology*, **2013**, 60, 36-46	5.8	48
341	Tissue-specific effects of acetylcholine in the canine heart. *American Journal of Physiology - Heart and Circulatory Physiology*, **2013**, 305, H66-75	5.2	16
340	Mechanisms of Action of Antiarrhythmic Drugs in Atrial Fibrillation **2013**, 141-156		
339	Case Scenario. *Survey of Anesthesiology*, **2013**, 57, 140-141		
338	Identification of a novel de novo mutation associated with PRKAG2 cardiac syndrome and early onset of heart failure. *PLoS ONE*, **2013**, 8, e64603	3.7	19
337	Brugada Syndrome: Cellular Mechanisms and Approaches to Therapy **2013**, 497-536		1
336	Long QT, syndactyly, joint contractures, stroke and novel CACNA1C mutation: expanding the spectrum of Timothy syndrome. *American Journal of Medical Genetics, Part A*, **2012**, 158A, 182-7	2.5	70

335	Genetic, molecular and cellular mechanisms underlying the J wave syndromes. *Circulation Journal*, **2012**, 76, 1054-65	2.9	123
334	The phenomenon of "QT stunning": the abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. *Heart Rhythm*, **2012**, 9, 901-8	6.7	59
333	Descripci□ de la utilizaci□ de cu□as ventriculares aisladas de coraz□ canino en el laboratorio de electrofisiolog□ experimental. *Cardiocore*, **2012**, 47, 127-129		
332	A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. *Heart Rhythm*, **2012**, 9, 760-9	6.7	84
331	Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. *Heart Rhythm*, **2012**, 9, 422-9	6.7	19
330	Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. *Heart Rhythm*, **2012**, 9, 125-31	6.7	57
329	Physiological consequences of transient outward K+ current activation during heart failure in the canine left ventricle. *Journal of Molecular and Cellular Cardiology*, **2012**, 52, 1291-8	5.8	29
328	A complete right bundle-branch block masking Brugada syndrome. *Journal of Electrocardiology*, **2012**, 45, 780-2	1.4	10
327	Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. *Heart Rhythm*, **2012**, 9, 1104-12	6.7	29
326	Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. *Heart Rhythm*, **2012**, 9, 548-55	6.7	120
325	Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. *Heart Rhythm*, **2012**, 9, 776-81	6.7	41
324	Novel mutations in the KCND3-encoded Kv4.3 K+ channel associated with autopsy-negative sudden unexplained death. *Human Mutation*, **2012**, 33, 989-97	4.7	48
323	Identification of specific pluripotent stem cell death--inducing small molecules by chemical screening. *Stem Cell Reviews and Reports*, **2012**, 8, 116-27	6.4	15
322	Ionic and cellular mechanisms underlying the development of acquired Brugada syndrome in patients treated with antidepressants. *Journal of Cardiovascular Electrophysiology*, **2012**, 23, 423-32	2.7	38
321	Mechanisms Underlying Arrhythmogenesis in Long QT Syndrome. *Cardiac Electrophysiology Clinics*, **2012**, 4, 17-27	1.4	6
320	Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. *Circulation*, **2012**, 125, 14-22	16.7	46
319	Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 340, 161-8	4.7	27
318	Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. *Circulation: Arrhythmia and Electrophysiology*, **2012**, 5, 400-8	6.4	39

317	Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine. *Circulation: Arrhythmia and Electrophysiology*, **2012**, 5, 371-9	6.4	21
316	Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. *Journal of Cardiovascular Pharmacology*, **2012**, 59, 539-46	3.1	19
315	Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr). *PLoS ONE*, **2012**, 7, e40288	3.7	110
314	Case scenario: anesthesia-related cardiac arrest in a child with Timothy syndrome. *Anesthesiology*, **2012**, 117, 1117-26	4.3	9
313	Human Induced Pluripotent Stem Cells: Role in Patient-Specific Drug Discovery **2012**, 257-263		
312	Overview of Basic Mechanisms of Cardiac Arrhythmia. *Cardiac Electrophysiology Clinics*, **2011**, 3, 23-45	1.4	174
311	Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. *Heart Rhythm*, **2011**, 8, 1546-52	6.7	17
310	Advances in the Pharmacologic Management of Atrial Fibrillation. *Cardiac Electrophysiology Clinics*, **2011**, 3, 157-167	1.4	
309	Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. *Journal of the American College of Cardiology*, **2011**, 57, 986-93	15.1	24
308	Rationale for the use of the terms J-wave syndromes and early repolarization. *Journal of the American College of Cardiology*, **2011**, 57, 1587-90	15.1	49
307	Ischemic ventricular arrhythmias: experimental models and their clinical relevance. *Heart Rhythm*, **2011**, 8, 1963-8	6.7	90
306	Electrophysiologic basis for the antiarrhythmic actions of ranolazine. *Heart Rhythm*, **2011**, 8, 1281-90	6.7	182
305	Short QT syndrome. *Neurology International*, **2011**, 1,	0	2
304	Pathophysiology of atrial fibrillation **2011**, 20-34		
303	Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations. *Journal of Cardiovascular Electrophysiology*, **2011**, 22, 698-705	2.7	12
302	Comparison of the effects of a transient outward potassium channel activator on currents recorded from atrial and ventricular cardiomyocytes. *Journal of Cardiovascular Electrophysiology*, **2011**, 22, 1057-66	2.7	27
301	J-wave syndromes. from cell to bedside. *Journal of Electrocardiology*, **2011**, 44, 656-61	1.4	40
300	Minimum Information about a Cardiac Electrophysiology Experiment (MICEE): standardised reporting for model reproducibility, interoperability, and data sharing. *Progress in Biophysics and Molecular Biology*, **2011**, 107, 4-10	4.7	45

299	Novel pharmacological targets for the rhythm control management of atrial fibrillation. *Pharmacology & Therapeutics*, **2011**, 132, 300-13	13.9	24
298	Multiple arrhythmic syndromes in a newborn, owing to a novel mutation in SCN5A. *Canadian Journal of Physiology and Pharmacology*, **2011**, 89, 723-36	2.4	5
297	Mechanisms of atrial-selective block of Na+ channels by ranolazine: II. Insights from a mathematical model. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 301, H1615-24	5.2	28
296	Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. *Heart Rhythm*, **2011**, 8, 1024-32	6.7	191
295	The J Wave Syndromes and their Role in Sudden Cardiac Death. *Cardiac Electrophysiology Clinics*, **2011**, 3, 47-56	1.4	2
294	Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation. *Future Cardiology*, **2011**, 7, 733-7	1.3	3
293	Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac voltage-dependent L-type calcium channel. *Circulation Research*, **2011**, 108, 607-18	15.7	60
292	Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). *European Heart Journal*, **2011**, 32, 1077-88	9.5	148
291	LQT5 masquerading as LQT2: a dominant negative effect of KCNE1-D85N rare polymorphism on KCNH2 current. *Europace*, **2011**, 13, 1478-83	3.9	18
290	Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry. *Circulation: Cardiovascular Genetics*, **2011**, 4, 51-7		24
289	Mechanisms of atrial-selective block of Na+ channels by ranolazine: I. Experimental analysis of the use-dependent block. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 301, H1606-14	5.2	50
288	Extracellular proton depression of peak and late Na+ current in the canine left ventricle. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 301, H936-44	5.2	30
287	Unraveling the Enigma of Bangungut: Is Sudden Unexplained Nocturnal Death Syndrome (SUNDS) in the Philippines a Disease Allelic to the Brugada Syndrome? **2011**, 49, 165-176		14
286	Ionic and Cellular Basis for Arrhythmogenesis **2011**, 41-64		2
285	Short QT Syndrome: Clinical Presentation, Molecular, Genetic, Cellular, and Ionic Basis **2011**, 441-451		
284	The Contribution of HCN4 to normal sinus node function in humans and animal models. *PACE - Pacing and Clinical Electrophysiology*, **2010**, 33, 100-6	1.6	26
283	Dual variation in SCN5A and CACNB2b underlies the development of cardiac conduction disease without Brugada syndrome. *PACE - Pacing and Clinical Electrophysiology*, **2010**, 33, 274-85	1.6	31
282	Transseptal dispersion of repolarization and its role in the development of Torsade de Pointes arrhythmias. *Journal of Cardiovascular Electrophysiology*, **2010**, 21, 441-7	2.7	33

281	A novel mutation in the HCN4 gene causes symptomatic sinus bradycardia in Moroccan Jews. *Journal of Cardiovascular Electrophysiology*, **2010**, 21, 1365-72	2.7	50
280	Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. *Annals of the New York Academy of Sciences*, **2010**, 1188, 78-86	6.5	22
279	M cells in the human heart. *Circulation Research*, **2010**, 106, 815-7	15.7	42
278	Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 334, 255-9	4.7	9
277	A common single nucleotide polymorphism can exacerbate long-QT type 2 syndrome leading to sudden infant death. *Circulation: Cardiovascular Genetics*, **2010**, 3, 199-206		41
276	The role of local voltage potentials in outflow tract ectopy. *Europace*, **2010**, 12, 850-60	3.9	16
275	Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. *European Heart Journal*, **2010**, 31, 330-9	9.5	155
274	New developments in atrial antiarrhythmic drug therapy. *Nature Reviews Cardiology*, **2010**, 7, 139-48	14.8	57
273	Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. *Circulation: Arrhythmia and Electrophysiology*, **2010**, 3, 88-95	6.4	66
272	Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. *Current Medicinal Chemistry*, **2010**, 17, 759-66	4.3	69
271	KCNH2-K897T Polymorphism Increases the Risk of Life-Threatening Arrhythmias Following Acute Myocardial Infarction. *Heart Rhythm*, **2010**, 7, 1720	6.7	3
270	Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. *Heart Rhythm*, **2010**, 7, 251-7	6.7	23
269	KCNE2 modulation of Kv4.3 current and its potential role in fatal rhythm disorders. *Heart Rhythm*, **2010**, 7, 199-205	6.7	24
268	An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. *Heart Rhythm*, **2010**, 7, 33-46	6.7	515
267	The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. *Journal of the American College of Cardiology*, **2010**, 55, 1955-61	15.1	149
266	Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. *Journal of the American College of Cardiology*, **2010**, 56, 1216-24	15.1	106
265	Differential effects of the transient outward K(+) current activator NS5806 in the canine left ventricle. *Journal of Molecular and Cellular Cardiology*, **2010**, 48, 191-200	5.8	40
264	Modulation of canine cardiac sodium current by Apelin. *Journal of Molecular and Cellular Cardiology*, **2010**, 48, 694-701	5.8	23

263	The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. *Journal of Molecular and Cellular Cardiology*, **2010**, 49, 543-53	5.8	251
262	Short QT syndrome: from bench to bedside. *Circulation: Arrhythmia and Electrophysiology*, **2010**, 3, 401-8	6.4	108
261	Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. *Heart Rhythm*, **2010**, 7, 1273-9	6.7	21
260	J wave syndromes. *Heart Rhythm*, **2010**, 7, 549-58	6.7	425
259	A gain-of-function I(K-ATP) mutation and its role in sudden cardiac death associated with J-wave syndromes. *Heart Rhythm*, **2010**, 7, 1472-4	6.7	9
258	Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. *Heart Rhythm*, **2010**, 7, 1872-82	6.7	324
257	Overlapping LQT1 and LQT2 phenotype in a patient with long QT syndrome associated with loss-of-function variations in KCNQ1 and KCNH2. *Canadian Journal of Physiology and Pharmacology*, **2010**, 88, 1181-90	2.4	10
256	AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. *Journal of Cardiovascular Pharmacology*, **2010**, 56, 80-90	3.1	24
255	Advances in the Pharmacological Treatment of Atrial Fibrillation **2010**, 29, 1-5		
254	Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation **2010**, 3, 108-113		1
253	Atrial-selective sodium channel block for the treatment of atrial fibrillation. *Expert Opinion on Emerging Drugs*, **2009**, 14, 233-49	3.7	29
252	Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. *Circulation: Arrhythmia and Electrophysiology*, **2009**, 2, 80-8	6.4	64
251	A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. *Circulation: Cardiovascular Genetics*, **2009**, 2, 270-8		199
250	Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. *Journal of Electrocardiology*, **2009**, 42, 543-8	1.4	43
249	Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. *Journal of Cardiovascular Electrophysiology*, **2009**, 20, 803-10	2.7	21
248	New pharmacological strategies for the treatment of atrial fibrillation. *Annals of Noninvasive Electrocardiology*, **2009**, 14, 290-300	1.5	19
247	Accelerated inactivation of the L-type calcium current due to a mutation in CACNB2b underlies Brugada syndrome. *Journal of Molecular and Cellular Cardiology*, **2009**, 46, 695-703	5.8	87
246	Biophysical Characterization of a Novel KCNJ2 Mutation Associated with Andersen-Tawil Syndrome and CPVT Mimicry. *Biophysical Journal*, **2009**, 96, 260a-261a	2.9	2

245	The acquired Brugada syndrome and the paradox of choice. *Heart Rhythm*, **2009**, 6, 1342-4	6.7	5
244	Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. *Heart Rhythm*, **2009**, 6, 401-4	6.7	92
243	Mechanism of the Preferential Block of the Atrial Sodium Current by Ranolazine. *Biophysical Journal*, **2009**, 96, 250a	2.9	4
242	AZD1305 has Atrial-Predominant Electrophysiologic Actions and is Effective in Suppressing Atrial Fibrillation in the Dog. *Heart Rhythm*, **2009**, 6, 1685	6.7	2
241	A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. *Cardiovascular Research*, **2009**, 81, 686-94	9.9	83
240	Novel Pharmacological Targets for the Management of Atrial Fibrillation **2009**, 461-478		
239	Genetics and Sinus Node Dysfunction. *Journal of Atrial Fibrillation*, **2009**, 1, 151	0.8	1
238	Cellular mechanism and arrhythmogenic potential of T-wave alternans in the Brugada syndrome. *Journal of Cardiovascular Electrophysiology*, **2008**, 19, 301-8	2.7	39
237	Pharmacological approach to the treatment of long and short QT syndromes **2008**, 118, 138-51		38
236	Atrial fibrillation and Brugada syndrome. *Journal of the American College of Cardiology*, **2008**, 51, 1149-53	15.1	87
235	Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. *Heart Rhythm*, **2008**, 5, 1726-34	6.7	64
234	Gain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillation. *Heart Rhythm*, **2008**, 5, 427-35	6.7	102
233	Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. *Heart Rhythm*, **2008**, 5, 241-5	6.7	52
232	Is a narrow and tall QRS complex an ECG marker for sudden death?. *Heart Rhythm*, **2008**, 5, 1339-45	6.7	23
231	Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. *Heart Rhythm*, **2008**, 5, 1019-26	6.7	103
230	To the Editor Response. *Heart Rhythm*, **2008**, 5, 1091-1092	6.7	1
229	Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. *Heart Rhythm*, **2008**, 5, 585-90	6.7	73
228	Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. *Heart Rhythm*, **2008**, 5, 1735-42	6.7	55

227	Can inhibition of IKur promote atrial fibrillation?. *Heart Rhythm*, **2008**, 5, 1304-9	6.7	44
226	Fever accentuates transmural dispersion of repolarization and facilitates development of early afterdepolarizations and torsade de pointes under long-QT Conditions. *Circulation: Arrhythmia and Electrophysiology*, **2008**, 1, 202-8	6.4	34
225	Sudden cardiac death secondary to antidepressant and antipsychotic drugs. *Expert Opinion on Drug Safety*, **2008**, 7, 181-94	4.1	82
224	Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel. *Circulation Research*, **2008**, 103, 396-404	15.7	36
223	Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2008**, 1, 209-18	6.4	256
222	Ranolazine: a new antiarrhythmic agent for patients with non-ST-segment elevation acute coronary syndromes?. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, 248-9		11
221	Augmentation of J waves and electrical storms in patients with early repolarization. *New England Journal of Medicine*, **2008**, 358, 2078-9	59.2	230
220	Atrial-selective sodium channel blockers: do they exist?. *Journal of Cardiovascular Pharmacology*, **2008**, 52, 121-8	3.1	43
219	Brugada syndrome: recent advances and controversies. *Current Cardiology Reports*, **2008**, 10, 376-83	4.2	40
218	Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. *Annals of the New York Academy of Sciences*, **2008**, 1123, 105-12	6.5	47
217	Study of the extent of the information of cardiologists from S□ Paulo city, Brazil, regarding a low-prevalence entity: Brugada syndrome. *Annals of Noninvasive Electrocardiology*, **2008**, 13, 352-63	1.5	2
216	Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. *Cardiovascular Research*, **2008**, 77, 481-8	9.9	60
215	Brugada Syndrome: Cellular Mechanisms and Approaches to Therapy **2008**, 500-535		1
214	Drug-induced spatial dispersion of repolarization. *Cardiology Journal*, **2008**, 15, 100-21	1.4	74
213	Risk stratification [corrected] of Brugada syndrome revisited. *Israel Medical Association Journal*, **2008**, 10, 462-4	0.9	2
212	How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?. *Journal of Atrial Fibrillation*, **2008**, 1, 98-107	0.8	15
211	Mechanisms of Cardiac Arrhythmia **2008**, 65-132		2
210	Abstract 4413: Accelerated Inactivation of the L-type Calcium due to a Mutation in CACNB2b Underlies the Development of a Brugada ECG Phenotype. *Circulation*, **2008**, 118,	16.7	1

209	Does Tpeak-Tend provide an index of transmural dispersion of repolarization?. *Heart Rhythm*, **2007**, 4, 1114-6; author reply 1116-9	6.7	196
208	Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction. *Heart Rhythm*, **2007**, 4, 1072-80	6.7	53
207	Genetic basis of Brugada syndrome. *Heart Rhythm*, **2007**, 4, 756-7	6.7	32
206	Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. *Heart Rhythm*, **2007**, 4, 638-47	6.7	70
205	Occurrence of "J waves" in 12-lead ECG as a marker of acute ischemia and their cellular basis. *PACE - Pacing and Clinical Electrophysiology*, **2007**, 30, 817-9	1.6	55
204	A novel mutation in KCNQ1 associated with a potent dominant negative effect as the basis for the LQT1 form of the long QT syndrome. *Journal of Cardiovascular Electrophysiology*, **2007**, 18, 972-7	2.7	24
203	Diagnostic and genetic aspects of the Brugada and other inherited arrhythmias syndromes. *Journal of Electrocardiology*, **2007**, 40, S11-S14	1.4	4
202	Imaging fibrillation/defibrillation in a dish. *Journal of Electrocardiology*, **2007**, 40, S62-5	1.4	5
201	Genetic predisposition and cellular basis for ischemia-induced ST-segment changes and arrhythmias. *Journal of Electrocardiology*, **2007**, 40, S26-9	1.4	19
200	Development of a coronary-perfused interventricular septal preparation as a model for studying the role of the septum in arrhythmogenesis. *Journal of Electrocardiology*, **2007**, 40, S142-4	1.4	4
199	Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 293, H2024-38	5.2	184
198	Cellular and subcellular alternans in the canine left ventricle. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 293, H3506-16	5.2	42
197	Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. *Europace*, **2007**, 9 Suppl 4, iv4-15	3.9	104
196	Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. *Circulation*, **2007**, 115, 442-9	16.7	731
195	Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. *Circulation*, **2007**, 116, 1449-57	16.7	330
194	Heterogeneity and cardiac arrhythmias: an overview. *Heart Rhythm*, **2007**, 4, 964-72	6.7	124
193	Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. *European Heart Journal*, **2006**, 27, 469-75	9.5	38
192	Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. *Circulation*, **2006**, 113, 1393-400	16.7	86

191	Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. *Circulation*, **2006**, 114, 2026-33	16.7	83
190	Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. *Heart Rhythm*, **2006**, 3, 1074-8	6.7	40
189	Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. *Heart Rhythm*, **2006**, 3, 948-56	6.7	103
188	Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and	16.7	2279
187	Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. *Heart Rhythm*, **2006**, 3, 131-7	6.7	127
186	Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). *Heart Rhythm*, **2006**, 3, 328-35	6.7	77
185	Functional expression of "cardiac-type" Nav1.5 sodium channel in canine intracardiac ganglia. *Heart Rhythm*, **2006**, 3, 842-50	6.7	41
184	Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. *Journal of the American College of Cardiology*, **2006**, 47, 1828-34	15.1	356
183	Disopyramide: although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome?. *Journal of Molecular and Cellular Cardiology*, **2006**, 41, 421-3	5.8	9
182	Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. *PACE - Pacing and Clinical Electrophysiology*, **2006**, 29, 290-5	1.6	98
181	Brugada syndrome. *PACE - Pacing and Clinical Electrophysiology*, **2006**, 29, 1130-59	1.6	273
180	The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. *Journal of Cardiovascular Electrophysiology*, **2006**, 17 Suppl 1, S79-S85	2.7	70
179	Amplification of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes. *Journal of Internal Medicine*, **2006**, 259, 48-58	10.8	104
178	Cellular basis for the repolarization waves of the ECG. *Annals of the New York Academy of Sciences*, **2006**, 1080, 268-81	6.5	53
177	Cardiac repolarization. The long and short of it. *Europace*, **2005**, 7 Suppl 2, 3-9	3.9	49
176	Biophysical basis for monophasic action potential. *Cardiovascular Research*, **2005**, 65, 942-944	9.9	13
175	Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. *Heart Rhythm*, **2005**, 2, S9-15	6.7	140
174	adrenergic stimulation is highly arrhythmogenic following ischemic/reperfusion injury in the isolated canine right atrium. *Heart Rhythm*, **2005**, 2, S179-S180	6.7	3

173	Brugada syndrome. *International Journal of Cardiology*, **2005**, 101, 173-8	3.2	21
172	The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. *Cell*, **2005**, 123, 347-58	56.2	200
171	Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. *Circulation*, **2005**, 111, 2727-33	16.7	87
170	Potential proarrhythmic effects of biventricular pacing. *Journal of the American College of Cardiology*, **2005**, 46, 2340-7	15.1	96
169	Brugada syndrome: report of the second consensus conference. *Heart Rhythm*, **2005**, 2, 429-40	6.7	329
168	Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. *Heart Rhythm*, **2005**, 2, 254-60	6.7	150
167	Modulation of transmural repolarization. *Annals of the New York Academy of Sciences*, **2005**, 1047, 314-23	6.5	41
166	Brugada syndrome: from cell to bedside. *Current Problems in Cardiology*, **2005**, 30, 9-54	17.1	86
165	Brugada syndrome and ischemia-induced ST-segment elevation. Similarities and differences. *Journal of Electrocardiology*, **2005**, 38, 14-7	1.4	44
164	Short QT syndrome. Genotype-phenotype correlations. *Journal of Electrocardiology*, **2005**, 38, 75-80	1.4	63
163	Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. *Journal of Cardiovascular Electrophysiology*, **2005**, 16, 54-8	2.7	154
162	Role of repolarization restitution in the development of coarse and fine atrial fibrillation in the isolated canine right atria. *Journal of Cardiovascular Electrophysiology*, **2005**, 16, 639-45	2.7	12
161	Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome. *Current Pharmaceutical Design*, **2005**, 11, 1561-72	3.3	61
160	Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. *Circulation*, **2005**, 111, 659-70	16.7	1356
159	Cellular, Molecular, and Pharmacologic Mechanisms Underlying Drug-Induced Cardiac Arrhythmogenesis **2005**, 37-66		
158	Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. *American Journal of Physiology - Heart and Circulatory Physiology*, **2004**, 286, H1471-9	5.2	152
157	Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 310, 599-605	4.7	162
156	Sudden death associated with short-QT syndrome linked to mutations in HERG. *Circulation*, **2004**, 109, 30-5	16.7	685

155	Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2004**, 9 Suppl 1, S65-83	2.6	104
154	Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. *Circulation*, **2004**, 110, 3661-6	16.7	174
153	Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing. *Circulation*, **2004**, 109, 2136-42	16.7	172
152	Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. *Circulation*, **2004**, 110, 904-10	16.7	547
151	Cellular basis for the monophasic action potential. Which electrode is the recording electrode?. *Cardiovascular Research*, **2004**, 63, 635-44	9.9	30
150	When u say "U Waves," what do u mean?. *PACE - Pacing and Clinical Electrophysiology*, **2004**, 27, 145-7	1.6	13
149	Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem?. *Journal of Electrocardiology*, **2004**, 37 Suppl, 15-24	1.4	85
148	Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A:. *Journal of Cardiovascular Electrophysiology*, **2004**, 15, 64-9	2.7	43
147	Drug-induced torsades de pointes and implications for drug development. *Journal of Cardiovascular Electrophysiology*, **2004**, 15, 475-95	2.7	272
146	Link between hypothermia and the Brugada syndrome. *Journal of Cardiovascular Electrophysiology*, **2004**, 15, 942-4	2.7	27
145	Cellular basis and mechanism underlying normal and abnormal myocardial repolarization and arrhythmogenesis. *Annals of Medicine*, **2004**, 36 Suppl 1, 5-14	1.5	71
144	Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. *Circulation*, **2004**, 110, 3023-7	16.7	129
143	Molecular genetics of arrhythmias and cardiovascular conditions associated with arrhythmias. *Heart Rhythm*, **2004**, 1, 42C-56C	6.7	9
142	Role of sodium and calcium channel block in unmasking the Brugada syndrome. *Heart Rhythm*, **2004** , 1, 210-7	6.7	131
141	Short QT syndrome: pharmacological treatment. *Journal of the American College of Cardiology*, **2004**, 43, 1494-9	15.1	278
140	Autonomic aspects of arrhythmogenesis: the enduring and the new. *Current Opinion in Cardiology*, **2004**, 19, 2-11	2.1	154
139	Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block. *American Journal of Physiology - Heart and Circulatory Physiology*, **2004**, 286, H2393-400	5.2	55
138	Drug-induced Channelopathies **2004**, 151-157		4

137	The Brugada Syndrome **2004**, 625-632		2
136	Brugada syndrome: 12 years of progression. *Acta Medica Okayama*, **2004**, 58, 255-61	0.5	2
135	Brugada syndrome: clinical, genetic, molecular, cellular and ionic aspects. *Expert Review of Cardiovascular Therapy*, **2003**, 1, 177-85	2.5	10
134	Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes?. *Circulation*, **2003**, 107, 740-6	16.7	288
133	Coordinated down-regulation of KCNQ1 and KCNE1 expression contributes to reduction of I(Ks) in canine hypertrophied hearts. *Cardiovascular Research*, **2003**, 57, 486-96	9.9	45
132	HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. *Journal of Cardiovascular Pharmacology*, **2003**, 41, 140-7	3.1	66
131	Expert's opinion. *Journal of Electrocardiology*, **2003**, 36, 165	1.4	1
130	Cellular basis for ST-segment changes observed during ischemia. *Journal of Electrocardiology*, **2003**, 36 Suppl, 1-5	1.4	51
129	Cellular and ionic basis for the sex-related difference in the manifestation of the Brugada syndrome and progressive conduction disease phenotypes. *Journal of Electrocardiology*, **2003**, 36 Suppl, 173-9	1.4	51
128	Cellular mechanisms underlying the long QT syndrome. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 114; author reply 114-5	2.7	8
127	Molecular genetics of arrhythmias and cardiovascular conditions associated with arrhythmias. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 1259-72	2.7	46
126	Molecular genetics of arrhythmias and cardiovascular conditions associated with arrhythmias. *PACE - Pacing and Clinical Electrophysiology*, **2003**, 26, 2194-208	1.6	13
125	Androgens and male predominance of the Brugada syndrome phenotype. *PACE - Pacing and Clinical Electrophysiology*, **2003**, 26, 1429-31	1.6	25
124	Brugada syndrome: 1992-2002: a historical perspective. *Journal of the American College of Cardiology*, **2003**, 41, 1665-71	15.1	146
123	Assessing predictors of drug-induced torsade de pointes. *Trends in Pharmacological Sciences*, **2003**, 24, 619-25	13.2	256
122	Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. *Circulation*, **2003**, 108, 1027-33	16.7	109
121	Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. *Circulation*, **2003**, 107, 2355-60	16.7	247
120	Cardiac Repolarization **2003**,		6

119	Brugada-like electrocardiographic pattern. *Indian Pacing and Electrophysiology Journal*, **2003**, 3, 91-2	1.5	
118	Contribution of Electrical Heterogeneity of Repolarization to the ECG. *Contemporary Cardiology*, **2003**, 111-126	0.1	
117	The Brugada Syndrome. *Contemporary Cardiology*, **2003**, 427-445	0.1	
116	ECG Phenomena of the Early Ventricular Repolarization. *Contemporary Cardiology*, **2003**, 407-425	0.1	1
115	How Do We Measure Repolarization Inside the Heart?. *Contemporary Cardiology*, **2003**, 91-110	0.1	
114	Electrophysiology and Pharmacology of Ventricular Repolarization. *Contemporary Cardiology*, **2003**, 63-89	0.1	
113	Cellular and Ionic Mechanisms Underlying Arrhythmogenesis. *Contemporary Cardiology*, **2003**, 201-251	0.1	1
112	Prominent I(Ks) in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations. *Journal of Cardiovascular Electrophysiology*, **2002**, 13, 172-7	2.7	51
111	The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option?. *PACE - Pacing and Clinical Electrophysiology*, **2002**, 25, 1634-40	1.6	84
110	ECG phenomenon of idiopathic and paradoxical short QT intervals. *Journal of Interventional Cardiac Electrophysiology*, **2002**, 6, 49-53		42
109	Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. *Circulation*, **2002**, 106, 2004-11	16.7	298
108	Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. *Circulation*, **2002**, 105, 1247-53	16.7	248
107	Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. *Circulation*, **2002**, 105, 73-8	16.7	462
106	Proposed diagnostic criteria for the Brugada syndrome: consensus report. *Circulation*, **2002**, 106, 2514-9	16.7	631
105	The Brugada syndrome. *Current Opinion in Cardiology*, **2002**, 17, 19-23	2.1	20
104	Cellular mechanisms underlying the long QT syndrome. *Current Opinion in Cardiology*, **2002**, 17, 43-51	2.1	207
103	Sympathetic modulation of the long QT syndrome. *European Heart Journal*, **2002**, 23, 1246-52	9.5	24
102	Electrical Heterogeneity in the Heart: Physiological, Pharmacological and Clinical Implications **2002**, 654-692		23

101	Molecular mechanisms underlying the long QT syndrome. *Current Opinion in Cardiology*, **2002**, 17, 36-42	2.1	28
100	Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. *Human Molecular Genetics*, **2002**, 11, 337-45	5.6	263
99	Novel mutations in domain I of SCN5A cause Brugada syndrome. *Molecular Genetics and Metabolism* , **2002**, 75, 317-24	3.7	52
98	Electrical heterogeneity within the ventricular wall. *Basic Research in Cardiology*, **2001**, 96, 517-27	11.8	257
97	T peak-Tend interval as an index of transmural dispersion of repolarization. *European Journal of Clinical Investigation*, **2001**, 31, 555-7	4.6	123
96	The Brugada syndrome: ionic basis and arrhythmia mechanisms. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 268-72	2.7	329
95	Chromanol 293B inhibits slowly activating delayed rectifier and transient outward currents in canine left ventricular myocytes. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 472-8	2.7	46
94	Cellular basis for complex T waves and arrhythmic activity following combined I(Kr) and I(Ks) block. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 1369-78	2.7	106
93	Clinical cardiac electrophysiology fellowship teaching objectives for the new millennium. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 1433-43	2.7	3
92	Molecular basis for the transmural distribution of the transient outward current. *Journal of Physiology*, **2001**, 533, 1	3.9	14
91	Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children. *Journal of Electrocardiology*, **2001**, 34 Suppl, 177-81	1.4	41
90	The Brugada syndrome: diagnostic criteria and cellular mechanisms. *European Heart Journal*, **2001**, 22, 356-63	9.5	74
89	Divergent expression of delayed rectifier K(+) channel subunits during mouse heart development. *Cardiovascular Research*, **2001**, 52, 65-75	9.9	52
88	Transmural dispersion of repolarization and the T wave. *Cardiovascular Research*, **2001**, 50, 426-31	9.9	76
87	New approaches to antiarrhythmic therapy: emerging therapeutic applications of the cell biology of cardiac arrhythmias(1). *Cardiovascular Research*, **2001**, 52, 345-60	9.9	17
86	The Brugada syndrome: clinical, genetic, cellular, and molecular abnormalities. *American Journal of Medicine*, **2001**, 110, 573-81	2.4	55
85	Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. *American Journal of Physiology - Heart and Circulatory Physiology*, **2001**, 281, H689-97	5.2	169
84	Basic mechanisms of reentrant arrhythmias. *Current Opinion in Cardiology*, **2001**, 16, 1-7	2.1	57

83	Cellular Basis for T Wave : Role of M Cells. *Japanese Journal of Electrocardiology*, **2001**, 21, 101-108	0	
82	Cardiac Arrhythmias: Reentry and Triggered Activity **2001**, 1153-1179		5
81	Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. *Journal of Cardiovascular Electrophysiology*, **2000**, 11, 1320-9	2.7	196
80	Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia. *Journal of Cardiovascular Electrophysiology*, **2000**, 11, 290-304	2.7	139
79	Block of I(Ks) does not induce early afterdepolarization activity but promotes beta-adrenergic agonist-induced delayed afterdepolarization activity. *Journal of Cardiovascular Electrophysiology*, **2000**, 11, 458-65	2.7	55
78	Cellular and ionic mechanisms responsible for the Brugada syndrome. *Journal of Electrocardiology*, **2000**, 33 Suppl, 33-9	1.4	42
77	I(NaCa) contributes to electrical heterogeneity within the canine ventricle. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 278, H1671-8	5.2	95
76	Electrical heterogeneity, cardiac arrhythmias, and the sodium channel. *Circulation Research*, **2000**, 87, 964-5	15.7	42
75	The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. *European Heart Journal*, **2000**, 21, 1216-31	9.5	286
74	A molecular link between the sudden infant death syndrome and the long-QT syndrome. *New England Journal of Medicine*, **2000**, 343, 262-7	59.2	296
73	Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. *Circulation*, **2000**, 102, 706-12	16.7	150
72	Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. *Circulation*, **2000**, 101, 510-5	16.7	639
71	Early repolarization syndrome: clinical characteristics and possible cellular and ionic mechanisms. *Journal of Electrocardiology*, **2000**, 33, 299-309	1.4	286
70	Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. *Journal of the American College of Cardiology*, **2000**, 35, 778-86	15.1	320
69	Brugada Syndrome Genetics. *Developments in Cardiovascular Medicine*, **2000**, 147-180		
68	Differences in the electrophysiologic response of four canine ventricular cell types to alpha 1-adrenergic agonists. *Cardiovascular Research*, **1999**, 43, 901-8	9.9	23
67	Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. *Circulation*, **1999**, 100, 1660-6	16.7	905
66	Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. *Circulation Research*, **1999**, 85, 803-9	15.7	469

65	Cellular and ionic basis for T-wave alternans under long-QT conditions. *Circulation*, **1999**, 99, 1499-507	16.7	268
64	The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. *Journal of Cardiovascular Electrophysiology*, **1999**, 10, 1124-52	2.7	436
63	Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome. *Journal of Cardiovascular Electrophysiology*, **1999**, 10, 154-64	2.7	105
62	The antifungal antibiotic clotrimazole potently inhibits L-type calcium current in guinea-pig ventricular myocytes. *British Journal of Pharmacology*, **1999**, 126, 1531-3	8.6	15
61	Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome. *Journal of Electrocardiology*, **1999**, 32 Suppl, 158-65	1.4	112
60	Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome. *Journal of Electrocardiology*, **1999**, 32 Suppl, 177-84	1.4	83
59	The Brugada syndrome: clinical, electrophysiologic and genetic aspects. *Journal of the American College of Cardiology*, **1999**, 33, 5-15	15.1	393
58	Ion channels and ventricular arrhythmias: cellular and ionic mechanisms underlying the Brugada syndrome. *Current Opinion in Cardiology*, **1999**, 14, 274-9	2.1	57
57	Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. *Nature*, **1998**, 392, 293-6	50.4	1455
56	Acceleration-induced action potential prolongation and early afterdepolarizations. *Journal of Cardiovascular Electrophysiology*, **1998**, 9, 934-48	2.7	106
55	The enigmatic ECG manifestation of Brugada syndrome. *Journal of Cardiovascular Electrophysiology*, **1998**, 9, 109-12	2.7	24
54	The Brugada syndrome. *Journal of Cardiovascular Electrophysiology*, **1998**, 9, 513-6	2.7	138
53	Cellular basis for the normal T wave and the ECG manifestations of the long QT syndrome. *Journal of Electrocardiology*, **1998**, 30, 148	1.4	2
52	Cellular basis for QT dispersion. *Journal of Electrocardiology*, **1998**, 30 Suppl, 168-75	1.4	190
51	Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. *Circulation*, **1998**, 98, 1928-36	16.7	790
50	Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. *Circulation*, **1998**, 98, 2314-22	16.7	439
49	Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. *Circulation*, **1998**, 98, 1921-7	16.7	383
48	The M Cell. *Journal of Cardiovascular Pharmacology and Therapeutics*, **1997**, 2, 73-76	2.6	32

47	Are M cells present in the ventricular myocardium of the pig? A question of maturity. *Cardiovascular Research*, **1997**, 36, 127-8	9.9	10
46	Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. *Journal of Cardiovascular Electrophysiology*, **1997**, 8, 1269-79	2.7	130
45	Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome. *Journal of Cardiovascular Electrophysiology*, **1997**, 8, 1280-90	2.7	64
44	Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. *Circulation*, **1997**, 96, 2038-47	16.7	357
43	Electrophysiological Characteristics of the M Cell **1997**, 212-226		5
42	Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. *Journal of the American College of Cardiology*, **1996**, 28, 1836-48	15.1	235
41	Evidence for the presence of M cells in the guinea pig ventricle. *Journal of Cardiovascular Electrophysiology*, **1996**, 7, 503-11	2.7	95
40	Cellular basis for the electrocardiographic J wave. *Circulation*, **1996**, 93, 372-9	16.7	557
39	The Contribution of K+ Currents to Electrical Heterogeneity Across the Canine Ventricular Wall under Normal and Ischemic Conditions. *Developments in Cardiovascular Medicine*, **1996**, 439-456		1
38	Electrophysiologic characteristics of M cells in the canine left ventricular free wall. *Journal of Cardiovascular Electrophysiology*, **1995**, 6, 591-603	2.7	87
37	Role of M cells in acquired long QT syndrome, U waves, and torsade de pointes. *Journal of Electrocardiology*, **1995**, 28 Suppl, 131-8	1.4	38
36	Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKs contributes to the longer action potential of the M cell. *Circulation Research*, **1995**, 76, 351-65	15.7	412
35	Distribution of M cells in the canine ventricle. *Journal of Cardiovascular Electrophysiology*, **1994**, 5, 824-37	2.7	115
34	Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. *Journal of the American College of Cardiology*, **1994**, 23, 259-77	15.1	410
33	Drug-induced afterdepolarizations and triggered activity occur in a discrete subpopulation of ventricular muscle cells (M cells) in the canine heart: quinidine and digitalis. *Journal of Cardiovascular Electrophysiology*, **1993**, 4, 48-58	2.7	94
32	Afterdepolarizations and triggered activity develop in a select population of cells (M cells) in canine ventricular myocardium: the effects of acetylstrophanthidin and Bay K 8644. *PACE - Pacing and Clinical Electrophysiology*, **1991**, 14, 1714-20	1.6	64
31	Effects of Milrinone on Atrioventricular Conduction in the Canine Heart Under Normal Conditions, During Atrial Flutter and After Ligation and Reperfusion of the Septal Artery. *Journal of Cardiovascular Electrophysiology*, **1990**, 1, 93-102	2.7	1
30	Quinidine-Induced Early Afterdepolarizations and Triggered Activity. *Journal of Electrophysiology*, **1989**, 3, 323-338		15

29	Rate dependence of action potential duration and refractoriness in canine ventricular endocardium differs from that of epicardium: role of the transient outward current. *Journal of the American College of Cardiology*, **1989**, 14, 1053-66	15.1	135
28	Reflected reentry, delayed conduction, and electrotonic inhibition in segmentally depressed atrial tissues. *Canadian Journal of Physiology and Pharmacology*, **1989**, 67, 757-64	2.4	23
27	The effects of milrinone on action potential characteristics, conduction, automaticity, and reflected reentry in isolated myocardial fibers. *Journal of Cardiovascular Pharmacology*, **1985**, 7, 341-9	3.1	18
26	Clinical Application of New Concepts of Parasystole, Reflection, and Tachycardia. *Cardiology Clinics*, **1983**, 1, 39-50	2.5	14
25	The case for modulated parasystole. *PACE - Pacing and Clinical Electrophysiology*, **1982**, 5, 911-26	1.6	72
24	The Role of Spatial Dispersion of Repolarization and Intramural Reentry in Inherited and Acquired Sudden Cardiac Death Syndromes1-17		
23	Rare syndromes, commotio cordis, sudden death in athletes1148-1198		1
22	Prognosis in Individuals with Brugada Syndrome184-193		
21	Atrial Tachyarrhythmias in Brugada Syndrome178-183		1
20	Treatment of Brugada Syndrome with an Implantable Cardioverter Defibrillator194-201		
19	Pharmacologic Approach to Therapy of Brugada Syndrome: Quinidine as an Alternative to ICD Therapy?202-211		1
18	Potential for Ablation Therapy in Patients with Brugada Syndrome212-220		
17	Value of 12 Lead Electrocardiogram and Derived Methodologies in the Diagnosis of Brugada Disease87-110		3
16	ST Segment Elevation and Sudden Death in the Athlete119-129		7
15	Brugada Syndrome: Role of Genetics in Clinical Practice130-139		1
14	Gender Differences in Brugada Syndrome149-156		
13	Predisposing Factors157-165		1
12	Acquired Forms of Brugada Syndrome166-177		12